Judge denies Intellia bid to throw out suit over $100m Regeneron pact

BlueAllele “plausibly alleged” that some of Intellia’s uses of technology were not reasonably related to FDA approval | Biotech claimed competitor received over $100m from Regeneron for using innovation to research therapeutic candidates.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

LSPN Awards USA: Meet the judges

10 April 2026 The 2026 panel has been chosen. With judges from Amgen, Pfizer, Eli Lilly, Takeda, Regeneron and law firms such as White & Case and Arnold & Porter, here’s who will be deciding this year’s winners.

Americas

Bausch reaches deal with competitor over IBS drug generic

7 April 2026 According to the settlement, MSN can maintain its challenge to several Bausch patents, while the details around potential product launch timings are unknown.

Americas

Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market

1 April 2026 After years of strict patent rules, Argentina is changing course. New IP reforms are putting the country back on the map, but how companies handle the transition will matter.

More features

LSPN Awards USA: Meet the judges

UK patent office adopts EPO standards for AI inventions

Faegre Drinker boosts FDA regulatory practice with two senior hires

Gilead to pay up to $5bn for antibody-drug conjugates push

Closing the women's health gap offers ‘benefits for all’

Bausch reaches deal with competitor over IBS drug generic

European patent offices raise fees

UPC refuses early knockout in Illumina–Element dispute

Judge denies Intellia bid to throw out suit over $100m Regeneron pact

More on this story

Editor's picks

Editor's picks

More features